Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK.

Manalan K, Green N, Arnold A, Cooke GS, Dedicoat M, Lipman M, Loyse A, Harrison TS, Kon OM.

J Infect. 2019 Sep 21. pii: S0163-4453(19)30277-4. doi: 10.1016/j.jinf.2019.09.006. [Epub ahead of print]

PMID:
31550466
2.

Recent advances in managing HIV-associated cryptococcal meningitis.

Boyer-Chammard T, Temfack E, Alanio A, Jarvis JN, Harrison TS, Lortholary O.

F1000Res. 2019 May 28;8. pii: F1000 Faculty Rev-743. doi: 10.12688/f1000research.17673.1. eCollection 2019. Review.

3.

Low-cerebrospinal fluid white cell counts and mortality in HIV-associated pneumococcal meningitis.

Tenforde MW, Meintjes G, Mokomane M, Harrison TS, Mine M, Jarvis JN.

AIDS. 2019 Jul 15;33(9):1539-1541. doi: 10.1097/QAD.0000000000002241. No abstract available.

PMID:
31259771
4.

Cryptococcal-related mortality despite fluconazole pre-emptive treatment in a cryptococcal antigen (CrAg) screen-and-treat programme.

Wake RM, Govender NP, Omar T, Nel C, Mazanderani AH, Karat AS, Ismail NA, Tiemessen CT, Jarvis JN, Harrison TS.

Clin Infect Dis. 2019 Jun 8. pii: ciz485. doi: 10.1093/cid/ciz485. [Epub ahead of print]

PMID:
31179488
5.

One year mortality outcomes from the ACTA trial of cryptococcal meningitis treatment in Malawi.

Kanyama C, Molloy SF, Chan AK, Lupiya D, Chawinga C, Adams J, Bright P, Lalloo DG, Heyderman RS, Lortholary O, Jaffar S, Loyse A, van Oosterhout JJ, Hosseinipour MC, Harrison TS.

Clin Infect Dis. 2019 Jun 1. pii: ciz454. doi: 10.1093/cid/ciz454. [Epub ahead of print]

PMID:
31155650
6.

Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: a cost-effectiveness analysis.

Kimaro GD, Guinness L, Shiri T, Kivuyo S, Chanda D, Bottomley C, Chen T, Kahwa A, Hawkins N, Mwaba P, Mfinanga SG, Harrison TS, Jaffar S, Niessen LW.

Clin Infect Dis. 2019 May 31. pii: ciz453. doi: 10.1093/cid/ciz453. [Epub ahead of print]

7.

AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study.

Ponatshego PL, Lawrence DS, Youssouf N, Molloy SF, Alufandika M, Bango F, Boulware DR, Chawinga C, Dziwani E, Gondwe E, Hlupeni A, Hosseinipour MC, Kanyama C, Meya DB, Mosepele M, Muthoga C, Muzoora CK, Mwandumba H, Ndhlovu CE, Rajasingham R, Sayed S, Shamu S, Tsholo K, Tugume L, Williams D, Maheswaran H, Shiri T, Boyer-Chammard T, Loyse A, Chen T, Wang D, Lortholary O, Lalloo DG, Meintjes G, Jaffar S, Harrison TS, Jarvis JN, Niessen LW.

BMJ Open. 2019 Apr 1;9(4):e026288. doi: 10.1136/bmjopen-2018-026288.

8.

Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa.

Chen T, Mwenge L, Lakhi S, Chanda D, Mwaba P, Molloy SF, Gheorghe A, Griffiths UK, Heyderman RS, Kanyama C, Kouanfack C, Mfinanga S, Chan AK, Temfack E, Kivuyo S, Hosseinipour MC, Lortholary O, Loyse A, Jaffar S, Harrison TS, Niessen LW; ACTA Trial Team.

Clin Infect Dis. 2019 Mar 13. pii: ciy971. doi: 10.1093/cid/ciy971. [Epub ahead of print]

9.

Addition of flucytosine to fluconazole for the treatment of cryptococcal meningitis in Africa: a multi-country cost-effectiveness analysis.

Shiri T, Loyse A, Mwenge L, Chen T, Lakhi S, Chanda D, Mwaba P, Molloy SF, Heyderman R, Kanyama C, Hosseinipour MC, Kouanfack C, Temfack E, Mfinanga S, Kivuyo S, Chan AK, Jarvis JN, Lortholary O, Jaffar S, Niessen LW, Harrison TS.

Clin Infect Dis. 2019 Feb 28. pii: ciz163. doi: 10.1093/cid/ciz163. [Epub ahead of print]

10.

Reply to Rajasingham and Boulware.

Jarvis JN, Harrison TS.

Clin Infect Dis. 2019 Jan 29. doi: 10.1093/cid/ciz040. [Epub ahead of print] No abstract available.

PMID:
30698672
11.

Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis.

Stone NR, Rhodes J, Fisher MC, Mfinanga S, Kivuyo S, Rugemalila J, Segal ES, Needleman L, Molloy SF, Kwon-Chung J, Harrison TS, Hope W, Berman J, Bicanic T.

J Clin Invest. 2019 Mar 1;129(3):999-1014. doi: 10.1172/JCI124516. Epub 2019 Jan 28.

12.

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.

Francis J, Zvada SP, Denti P, Hatherill M, Charalambous S, Mungofa S, Dawson R, Dorman S, Gupte N, Wiesner L, Jindani A, Harrison TS, Olagunju A, Egan D, Owen A, McIlleron HM.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01964-18. doi: 10.1128/AAC.01964-18. Print 2019 Apr.

13.

Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.

Lawrence DS, Youssouf N, Molloy SF, Alanio A, Alufandika M, Boulware DR, Boyer-Chammard T, Chen T, Dromer F, Hlupeni A, Hope W, Hosseinipour MC, Kanyama C, Lortholary O, Loyse A, Meya DB, Mosepele M, Muzoora C, Mwandumba HC, Ndhlovu CE, Niessen L, Schutz C, Stott KE, Wang D, Lalloo DG, Meintjes G, Jaffar S, Harrison TS, Jarvis JN.

Trials. 2019 Jan 14;20(1):48. doi: 10.1186/s13063-018-3155-9.

14.

Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal Virulence.

Park YD, Jarvis JN, Hu G, Davis SE, Qiu J, Zhang N, Hollingsworth C, Loyse A, Gardina PJ, Valyi-Nagy T, Myers TG, Harrison TS, Bicanic T, Williamson PR.

MBio. 2018 Dec 18;9(6). pii: e02353-18. doi: 10.1128/mBio.02353-18.

15.

High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis.

Zhao HZ, Wang RY, Wang X, Jiang YK, Zhou LH, Cheng JH, Huang LP, Harrison TS, Zhu LP.

BMC Infect Dis. 2018 Dec 12;18(1):643. doi: 10.1186/s12879-018-3460-7.

16.

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.

Lawrence DS, Youssouf N, Molloy SF, Alanio A, Alufandika M, Boulware DR, Boyer-Chammard T, Chen T, Dromer F, Hlupeni A, Hope W, Hosseinipour MC, Kanyama C, Lortholary O, Loyse A, Meya DB, Mosepele M, Muzoora C, Mwandumba HC, Ndhlovu CE, Niessen L, Schutz C, Stott KE, Wang D, Lalloo DG, Meintjes G, Jaffar S, Harrison TS, Jarvis JN.

Trials. 2018 Nov 23;19(1):649. doi: 10.1186/s13063-018-3026-4. Erratum in: Trials. 2019 Jan 14;20(1):48.

17.

Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.

Loyse A, Burry J, Cohn J, Ford N, Chiller T, Ribeiro I, Koulla-Shiro S, Mghamba J, Ramadhani A, Nyirenda R, Aliyu SH, Wilson D, Le T, Oladele R, Lesikari S, Muzoora C, Kalata N, Temfack E, Mapoure Y, Sini V, Chanda D, Shimwela M, Lakhi S, Ngoma J, Gondwe-Chunda L, Perfect C, Shroufi A, Andrieux-Meyer I, Chan A, Schutz C, Hosseinipour M, Van der Horst C, Klausner JD, Boulware DR, Heyderman R, Lalloo D, Day J, Jarvis JN, Rodrigues M, Jaffar S, Denning D, Migone C, Doherty M, Lortholary O, Dromer F, Stack M, Molloy SF, Bicanic T, van Oosterhout J, Mwaba P, Kanyama C, Kouanfack C, Mfinanga S, Govender N, Harrison TS.

Lancet Infect Dis. 2019 Apr;19(4):e143-e147. doi: 10.1016/S1473-3099(18)30493-6. Epub 2018 Oct 18. Review.

PMID:
30344084
18.

Ischemic stroke as a complication of cryptococcal meningitis and immune reconstitution inflammatory syndrome: a case report.

Ellis JP, Kalata N, Joekes EC, Kampondeni S, Benjamin LA, Harrison TS, Lalloo DG, Heyderman RS.

BMC Infect Dis. 2018 Oct 16;18(1):520. doi: 10.1186/s12879-018-3386-0.

19.

The treatment of a pregnant HIV positive patient with cryptococcal meningitis in Malawi. Case report and review of treatment options.

Bright PD, Lupiya D, van Oosterhout JJ, Chen A, Harrison TS, Chan AK.

Med Mycol Case Rep. 2017 Oct 28;19:9-12. doi: 10.1016/j.mmcr.2017.10.002. eCollection 2018 Mar.

20.

Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis.

Molloy SF, Bradley J, Karunaharan N, Mputu M, Stone N, Phulusa J, Chawinga C, Gaskell K, Segula D, Ming D, Peirse M, Chanda D, Lakhi S, Loyse A, Kanyama C, Heyderman RS, Harrison TS.

AIDS. 2018 Sep 24;32(15):2259-2261. doi: 10.1097/QAD.0000000000001961.

21.

Understanding Causal Pathways in Cryptococcal Meningitis Immune Reconstitution Inflammatory Syndrome.

Jarvis JN, Harrison TS.

J Infect Dis. 2019 Jan 9;219(3):344-346. doi: 10.1093/infdis/jiy448. No abstract available.

22.

Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial.

Jarvis JN, Leeme TB, Molefi M, Chofle AA, Bidwell G, Tsholo K, Tlhako N, Mawoko N, Patel RKK, Tenforde MW, Muthoga C, Bisson GP, Kidola J, Changalucha J, Lawrence D, Jaffar S, Hope W, Molloy SLF, Harrison TS.

Clin Infect Dis. 2019 Jan 18;68(3):393-401. doi: 10.1093/cid/ciy515.

23.

The Cryptococcus neoformans Titan cell is an inducible and regulated morphotype underlying pathogenesis.

Dambuza IM, Drake T, Chapuis A, Zhou X, Correia J, Taylor-Smith L, LeGrave N, Rasmussen T, Fisher MC, Bicanic T, Harrison TS, Jaspars M, May RC, Brown GD, Yuecel R, MacCallum DM, Ballou ER.

PLoS Pathog. 2018 May 18;14(5):e1006978. doi: 10.1371/journal.ppat.1006978. eCollection 2018 May.

24.

Brief Report: Point of Care Cryptococcal Antigen Screening: Pipetting Finger-Prick Blood Improves Performance of Immunomycologics Lateral Flow Assay.

Wake RM, Jarvis JN, Harrison TS, Govender NP.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):574-578. doi: 10.1097/QAI.0000000000001721.

25.

The first 5 years of Part 2A Orders: the use of powers from court applications to protect public health in England 2010-15.

Arnold A, Bickler G, Harrison TS.

J Public Health (Oxf). 2019 Mar 1;41(1):27-35. doi: 10.1093/pubmed/fdy028.

PMID:
29590423
26.

Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa.

Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, Mfinanga S, Temfack E, Lakhi S, Lesikari S, Chan AK, Stone N, Kalata N, Karunaharan N, Gaskell K, Peirse M, Ellis J, Chawinga C, Lontsi S, Ndong JG, Bright P, Lupiya D, Chen T, Bradley J, Adams J, van der Horst C, van Oosterhout JJ, Sini V, Mapoure YN, Mwaba P, Bicanic T, Lalloo DG, Wang D, Hosseinipour MC, Lortholary O, Jaffar S, Harrison TS; ACTA Trial Study Team.

N Engl J Med. 2018 Mar 15;378(11):1004-1017. doi: 10.1056/NEJMoa1710922.

27.

Biphilic Organophosphorus-Catalyzed Intramolecular Csp2-H Amination: Evidence for a Nitrenoid in Catalytic Cadogan Cyclizations.

Nykaza TV, Ramirez A, Harrison TS, Luzung MR, Radosevich AT.

J Am Chem Soc. 2018 Feb 28;140(8):3103-3113. doi: 10.1021/jacs.7b13803. Epub 2018 Feb 12.

28.

High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients.

Wake RM, Britz E, Sriruttan C, Rukasha I, Omar T, Spencer DC, Nel JS, Mashamaite S, Adelekan A, Chiller TM, Jarvis JN, Harrison TS, Govender NP.

Clin Infect Dis. 2018 Feb 10;66(5):686-692. doi: 10.1093/cid/cix872.

29.

Long-term Mortality and Disability in Cryptococcal Meningitis: A Systematic Literature Review.

Pasquier E, Kunda J, De Beaudrap P, Loyse A, Temfack E, Molloy SF, Harrison TS, Lortholary O.

Clin Infect Dis. 2018 Mar 19;66(7):1122-1132. doi: 10.1093/cid/cix870.

PMID:
29028957
30.

Cryptococcal meningitis.

Ming DK, Harrison TS.

Br J Hosp Med (Lond). 2017 Aug 2;78(8):C125-C127. doi: 10.12968/hmed.2017.78.8.C125. No abstract available.

PMID:
28783390
31.

Fungal infections in HIV/AIDS.

Limper AH, Adenis A, Le T, Harrison TS.

Lancet Infect Dis. 2017 Nov;17(11):e334-e343. doi: 10.1016/S1473-3099(17)30303-1. Epub 2017 Jul 31. Review.

PMID:
28774701
32.

Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.

Arnold A, Cooke GS, Kon OM, Dedicoat M, Lipman M, Loyse A, Chis Ster I, Harrison TS.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e02586-16. doi: 10.1128/AAC.02586-16. Print 2017 Sep.

33.

Tracing Genetic Exchange and Biogeography of Cryptococcus neoformans var. grubii at the Global Population Level.

Rhodes J, Desjardins CA, Sykes SM, Beale MA, Vanhove M, Sakthikumar S, Chen Y, Gujja S, Saif S, Chowdhary A, Lawson DJ, Ponzio V, Colombo AL, Meyer W, Engelthaler DM, Hagen F, Illnait-Zaragozi MT, Alanio A, Vreulink JM, Heitman J, Perfect JR, Litvintseva AP, Bicanic T, Harrison TS, Fisher MC, Cuomo CA.

Genetics. 2017 Sep;207(1):327-346. doi: 10.1534/genetics.117.203836. Epub 2017 Jul 5.

34.

Cryptococcal meningitis: A neglected NTD?

Molloy SF, Chiller T, Greene GS, Burry J, Govender NP, Kanyama C, Mfinanga S, Lesikari S, Mapoure YN, Kouanfack C, Sini V, Temfack E, Boulware DR, Dromer F, Denning DW, Day J, Stone NRH, Bicanic T, Jarvis JN, Lortholary O, Harrison TS, Jaffar S, Loyse A.

PLoS Negl Trop Dis. 2017 Jun 29;11(6):e0005575. doi: 10.1371/journal.pntd.0005575. eCollection 2017 Jun. No abstract available.

35.

A Biphilic Phosphetane Catalyzes N-N Bond-Forming Cadogan Heterocyclization via PIII/PV═O Redox Cycling.

Nykaza TV, Harrison TS, Ghosh A, Putnik RA, Radosevich AT.

J Am Chem Soc. 2017 May 24;139(20):6839-6842. doi: 10.1021/jacs.7b03260. Epub 2017 May 10.

36.

Immune correlates of HIV-associated cryptococcal meningitis.

Tenforde MW, Scriven JE, Harrison TS, Jarvis JN.

PLoS Pathog. 2017 Mar 23;13(3):e1006207. doi: 10.1371/journal.ppat.1006207. eCollection 2017 Mar. Review. No abstract available.

37.

The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies.

Kimaro GD, Mfinanga S, Simms V, Kivuyo S, Bottomley C, Hawkins N, Harrison TS, Jaffar S, Guinness L; REMSTART trial team.

PLoS One. 2017 Feb 24;12(2):e0171917. doi: 10.1371/journal.pone.0171917. eCollection 2017.

38.

A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection.

Rhodes J, Beale MA, Vanhove M, Jarvis JN, Kannambath S, Simpson JA, Ryan A, Meintjes G, Harrison TS, Fisher MC, Bicanic T.

G3 (Bethesda). 2017 Apr 3;7(4):1165-1176. doi: 10.1534/g3.116.037499.

39.

The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of Cryptococcosis.

Kwon-Chung KJ, Bennett JE, Wickes BL, Meyer W, Cuomo CA, Wollenburg KR, Bicanic TA, Castañeda E, Chang YC, Chen J, Cogliati M, Dromer F, Ellis D, Filler SG, Fisher MC, Harrison TS, Holland SM, Kohno S, Kronstad JW, Lazera M, Levitz SM, Lionakis MS, May RC, Ngamskulrongroj P, Pappas PG, Perfect JR, Rickerts V, Sorrell TC, Walsh TJ, Williamson PR, Xu J, Zelazny AM, Casadevall A.

mSphere. 2017 Jan 11;2(1). pii: e00357-16. doi: 10.1128/mSphere.00357-16. eCollection 2017 Jan-Feb.

40.

Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008-2014.

Arnold A, Cooke GS, Kon OM, Dedicoat M, Lipman M, Loyse A, Butcher PD, Ster IC, Harrison TS.

J Infect. 2017 Mar;74(3):260-271. doi: 10.1016/j.jinf.2016.12.005. Epub 2016 Dec 18.

41.

Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy.

Williamson PR, Jarvis JN, Panackal AA, Fisher MC, Molloy SF, Loyse A, Harrison TS.

Nat Rev Neurol. 2017 Jan;13(1):13-24. doi: 10.1038/nrneurol.2016.167. Epub 2016 Nov 25. Review.

PMID:
27886201
42.

Genomic epidemiology of Cryptococcus yeasts identifies adaptation to environmental niches underpinning infection across an African HIV/AIDS cohort.

Vanhove M, Beale MA, Rhodes J, Chanda D, Lakhi S, Kwenda G, Molloy S, Karunaharan N, Stone N, Harrison TS, Bicanic T, Fisher MC.

Mol Ecol. 2017 Apr;26(7):1991-2005. doi: 10.1111/mec.13891. Epub 2016 Nov 8.

43.

XDR-TB transmission in London: Case management and contact tracing investigation assisted by early whole genome sequencing.

Arnold A, Witney AA, Vergnano S, Roche A, Cosgrove CA, Houston A, Gould KA, Hinds J, Riley P, Macallan D, Butcher PD, Harrison TS.

J Infect. 2016 Sep;73(3):210-8. doi: 10.1016/j.jinf.2016.04.037. Epub 2016 Jun 14.

PMID:
27311749
44.

A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis.

Jindani A, Borgulya G, de Patiño IW, Gonzales T, de Fernandes RA, Shrestha B, Atwine D, Bonnet M, Burgos M, Dubash F, Patel N, Checkley AM, Harrison TS, Mitchison D; International Consortium for Trials of Chemotherapeutic Agents in Tuberculosis, St George's University of London.

Int J Tuberc Lung Dis. 2016 Jun;20(6):832-8. doi: 10.5588/ijtld.15.0577.

PMID:
27155189
45.

Forgotten but not gone: HIV-associated cryptococcal meningitis.

Jarvis JN, Harrison TS.

Lancet Infect Dis. 2016 Jul;16(7):756-758. doi: 10.1016/S1473-3099(16)00128-6. Epub 2016 Mar 10. No abstract available.

PMID:
26971080
46.

Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.

Longley N, Jarvis JN, Meintjes G, Boulle A, Cross A, Kelly N, Govender NP, Bekker LG, Wood R, Harrison TS.

Clin Infect Dis. 2016 Mar 1;62(5):581-587. doi: 10.1093/cid/civ936. Epub 2015 Nov 12.

47.

Cryptococcal antigen screening in HIV-infected adults: let's get straight to the point.

Wake RM, Glencross DK, Sriruttan C, Harrison TS, Govender NP.

AIDS. 2016 Jan 28;30(3):339-42. doi: 10.1097/QAD.0000000000000967. No abstract available.

PMID:
26558733
48.

Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.

Bicanic T, Bottomley C, Loyse A, Brouwer AE, Muzoora C, Taseera K, Jackson A, Phulusa J, Hosseinipour MC, van der Horst C, Limmathurotsakul D, White NJ, Wilson D, Wood R, Meintjes G, Harrison TS, Jarvis JN.

Antimicrob Agents Chemother. 2015 Dec;59(12):7224-31. doi: 10.1128/AAC.01698-15. Epub 2015 Sep 8.

49.

Poor specificity of urinary cryptococcal antigen testing: Reply to Drain et al. Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu-Natal.

Tenforde MW, Longley N, Meya DB, Boulware DR, Meintjes G, Goercke I, Harrison TS, Jarvis JN.

HIV Med. 2018 Feb;19(2):e47-e48. doi: 10.1111/hiv.12319. Epub 2015 Sep 7. No abstract available.

50.

Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa.

Beale MA, Sabiiti W, Robertson EJ, Fuentes-Cabrejo KM, O'Hanlon SJ, Jarvis JN, Loyse A, Meintjes G, Harrison TS, May RC, Fisher MC, Bicanic T.

PLoS Negl Trop Dis. 2015 Jun 25;9(6):e0003847. doi: 10.1371/journal.pntd.0003847. eCollection 2015.

Supplemental Content

Loading ...
Support Center